Current management of patients with RPE65 mutation-associated Inherited Retinal Degenerations (RPE65-IRD) in Europe. Results of a 2 years follow-up multinational survey.
Sign Up to like & getrecommendations! Published in 2023 at "Ophthalmic research"
DOI: 10.1159/000529777
Abstract: INTRODUCTION To evaluate the current management of RPE65-biallelic mutation-associated inherited retinal degeneration (RPE65-IRD) in Europe since market authorization of Voretigene Neparvovec (VN, LuxturnaTM) in 2018. By July 2022, over 200 patients have been treated outside… read more here.
Keywords: rpe65 ird; mutation associated; survey; management ... See more keywords